Literature DB >> 12464957

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.

Christopher E Brightling1, Fiona A Symon, Surinder S Birring, Peter Bradding, Ian D Pavord, Andrew J Wardlaw.   

Abstract

BACKGROUND: Asthma is characterized by variable airflow obstruction and airway hyperresponsiveness in association with airway inflammation under the influence of T(H)2 cytokines. Eosinophilic bronchitis has similar immunopathology to asthma but without disordered airway physiology. Whether eosinophilic bronchitis is associated with increased expression of T(H)2 cytokines is unknown.
OBJECTIVE: We sought to assess the expression of T(H)2 cytokines in eosinophilic bronchitis.
METHODS: Expression of activation markers and chemokine receptors from blood and bronchoalveolar lavage (BAL) fluid T cells and the T(H)2 cytokine expression from these T cells and bronchial mucosa biopsy specimens were assessed from subjects with eosinophilic bronchitis, subjects with asthma, and healthy control subjects.
RESULTS: The proportion of resting (stimulated) CD4 BAL fluid T cells expressing intracellular IL-4 was significantly higher in the subjects with eosinophilic bronchitis 7.2% (11.4%) and subjects with asthma 5.3% (5.5%) than in healthy control subjects 2.8% (3.9%) (P =.03). The number of IL-4(+) (P <.001) and IL-5(+) (P =.003) cells per square millimeter of bronchial submucosa was significantly higher in the disease groups than in the healthy control subjects. Expression of intracellular IFN-gamma was significantly higher in stimulated blood CD8 T cells from subjects with eosinophilic bronchitis (24%) and asthma (17%) than in the healthy control subjects (5%; P =.003). There were no between-group differences in expression of IFN-gamma in the BAL fluid T cells or in the bronchial submucosa and no differences in expression of activation markers or chemokine receptors.
CONCLUSION: These findings support the concept of asthma as a disease associated with activation of T(H)2 lymphocytes in the airway and provide evidence that these cytokines play a role in the development of airway inflammation in eosinophilic bronchitis but suggest that the release of T(H)2 cytokines is not sufficient for the elaboration of disordered airway physiology in asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464957     DOI: 10.1067/mai.2002.129698

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  64 in total

1.  Increased nicotinamide adenine dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in asthma.

Authors:  Amanda Sutcliffe; Fay Hollins; Edith Gomez; Ruth Saunders; Camille Doe; Marcus Cooke; R A John Challiss; Chris E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2011-11-22       Impact factor: 21.405

2.  An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Authors:  Chad K Oh; Raffaella Faggioni; Feng Jin; Lorin K Roskos; Bing Wang; Claire Birrell; Rosamund Wilson; Nestor A Molfino
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

3.  Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma.

Authors:  Marjannie Eloi Akintunde; Melissa Rose; Paula Krakowiak; Luke Heuer; Paul Ashwood; Robin Hansen; Irva Hertz-Picciotto; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2015-07-11       Impact factor: 3.478

Review 4.  Chemokines and their receptors as potential targets for the treatment of asthma.

Authors:  C Palmqvist; A J Wardlaw; P Bradding
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

5.  Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1.

Authors:  Lucy Woodman; Salman Siddiqui; Glenn Cruse; Amanda Sutcliffe; Ruth Saunders; Davinder Kaur; Peter Bradding; Christopher Brightling
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 6.  Cytokine and anti-cytokine therapy in asthma: ready for the clinic?

Authors:  D Desai; C Brightling
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  Increased Sputum IL-17A Level in Non-asthmatic Eosinophilic Bronchitis.

Authors:  Chen Zhan; Rong Xu; Jiaxing Liu; Shengfang Zhang; Wei Luo; Ruchong Chen; Kefang Lai
Journal:  Lung       Date:  2018-10-01       Impact factor: 2.584

8.  Eosinophilic bronchitis, eosinophilia associated genetic variants, and notch signaling in asthma.

Authors:  Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2010-05-17       Impact factor: 5.764

9.  A novel method for isolation of human lung T cells from lung resection tissue reveals increased expression of GAPDH and CXCR6.

Authors:  C E Day; S D Zhang; J Riley; T Gant; A J Wardlaw; C Guillen
Journal:  J Immunol Methods       Date:  2009-01-06       Impact factor: 2.303

10.  Dyspnea and wheezing after adenosine injection in a patient with eosinophilic bronchitis.

Authors:  Rodrigo Cartin-Ceba; Marie Christine Aubry; Kaiser Lim
Journal:  Case Rep Med       Date:  2009-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.